Humacyte (HUMA) Operating Expenses (2020 - 2026)

Humacyte (HUMA) has reported Operating Expenses for 7 consecutive years, with $27.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses fell 8.75% year-over-year to $27.4 million in Q2 2026; TTM through Jun 2026 was $113.3 million, a 1.1% increase from a year earlier, with the FY2025 full-year figure at $110.2 million, down 3.69% from the prior year.
• Operating Expenses was $27.4 million for Q2 2026 at Humacyte, down from $29.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $31.3 million in Q4 2025 and troughed at $19.8 million in Q2 2022.
• A 5-year average of $26.0 million and a median of $26.4 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 34.79% in 2023 and declined 16.84% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $20.8 million in 2022, then rose by 25.94% to $26.2 million in 2023, then gained by 7.28% to $28.1 million in 2024, then gained by 11.45% to $31.3 million in 2025, then slipped by 12.46% to $27.4 million in 2026.
• The last three Operating Expenses figures came in at $27.4 million (Q2 2026), $29.4 million (Q1 2026), and $31.3 million (Q4 2025), per Business Quant data.